Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Extended Adjuvant Endocrine Therapy in Breast Cancer
2023-506135-14-00Phase 4Authorised
- Sponsor
- Region Örebro län
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of exemestane, anastrozole, tamoxifen and letrozole in breast cancer (4 cohorts), sponsored by Region Örebro län. Primary endpoint: Overall survival. Planned start Oct 2023; status: authorised.
02
Drugs
exemestaneanastrozoletamoxifenletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-506135-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506135-14-00.